The ratings of 30 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Shire PLC Sponsored ADR (SHPG) drops from a C to a D rating. Shire PLC Sponsored ADR a biopharmaceutical company, researches, develops, manufactures, sells, and distributes pharmaceutical products. The company also gets F’s in operating margin growth. For more information, get Portfolio Grader’s complete analysis of SHPG stock.

Vertex Pharmaceuticals Incorporated’s (VRTX) rating weakens this week, dropping to a F versus last week’s D. Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of VRTX stock.

Radius Health Inc (RDUS) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of RDUS stock.

This is a rough week for Alkermes Plc (ALKS). The company’s rating falls to D from the previous week’s C. Alkermes Plc is a fully integrated biotechnology company committed to developing medicines that will improve patients’ lives. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of ALKS stock.

Neurocrine Biosciences, Inc. (NBIX) earns a D this week, moving down from last week’s grade of C. Neurocrine Biosciences, Inc. is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of NBIX stock.

Loxo Oncology Inc (LOXO) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in earnings revisions, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of LOXO stock.

This week, La Jolla Pharmaceutical Company’s (LJPC) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of LJPC stock.

Otonomy, Inc. (OTIC) declines this week from a C to a D. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of OTIC stock.

Aduro BioTech, Inc. (ADRO) slips from a D to a F this week. For more information, get Portfolio Grader’s complete analysis of ADRO stock.

Insys Therapeutics, Inc. (INSY) gets weaker ratings this week as last week’s D drops to a F. Insys Therapeutics, Inc. develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company also gets F’s in sales growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of INSY stock.

Slipping from a C to a D rating, Aquinox Pharmaceuticals, Inc. (AQXP) takes a hit this week. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AQXP stock.

Dynavax Technologies Corporation (DVAX) earns a F this week, moving down from last week’s grade of D. Dynavax Technologies Corporation discovers and develops novel products to prevent and treat infectious diseases, asthma and inflammatory and autoimmune diseases. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of DVAX stock.

Slipping from a C to a D rating, Invitae Corp. (NVTA) takes a hit this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of NVTA stock.

This is a rough week for Inotek Pharmaceuticals Corporation (ITEK). The company’s rating falls to D from the previous week’s C. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ITEK stock.

Achillion Pharmaceuticals, Inc. (ACHN) gets weaker ratings this week as last week’s C drops to a D. Achillion Pharmaceuticals, Inc. focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The company also gets F’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ACHN stock.

OvaScience, Inc. (OVAS) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of OVAS stock.

This week, Trevena, Inc. (TRVN) drops from a D to a F rating. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TRVN stock.

GlycoMimetics, Inc. (GLYC) slips from a C to a D this week. The company also gets F’s in sales growth, earnings growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of GLYC stock.

Vital Therapies, Inc. (VTL) declines this week from a B to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of VTL stock.

Ignyta, Inc.’s (RXDX) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of RXDX stock.

This week, ZIOPHARM Oncology, Inc.’s (ZIOP) rating worsens to a F from the company’s D rating a week ago. ZIOPHARM Oncology, Inc. is a biopharmaceutical company that engages in the development and commercialization of small molecule and synthetic biology approaches to cancer therapies in the United States. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ZIOP stock.

Sunesis Pharmaceuticals, Inc. (SNSS) is having a tough week. The company’s rating falls from a C to a D. Sunesis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development and commercialization of novel small molecule therapeutics for oncology. The company also gets F’s in sales growth, earnings surprise, earnings momentum, and free cash flow. For more information, get Portfolio Grader’s complete analysis of SNSS stock.

Genocea Biosciences, Inc. (GNCA) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of GNCA stock.

Sangamo BioSciences, Inc. (SGMO) experiences a ratings drop this week, going from last week’s D to a F. Sangamo BioSciences, Inc. is engaged in the research, development and commercialization of novel transcription factors for gene regulation and gene modification. The company also gets F’s in sales growth, earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of SGMO stock.

Celldex Therapeutics, Inc. (CLDX) is having a tough week. The company’s rating falls from a D to a F. Celldex Therapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CLDX stock.

Regulus Therapeutics Inc. (RGLS) earns a F this week, moving down from last week’s grade of D. Regulus Therapeutics Inc. focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RGLS stock.

Fortress Biotech, Inc. (FBIO) declines this week from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FBIO stock.

Slipping from a C to a D rating, QLT Inc. (QLTI) takes a hit this week. QLT Inc. develops and commercializes pharmaceutical products for use in photodynamic therapy, the use of light activated drugs to treat disease. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of QLTI stock.

This is a rough week for Pieris Pharmaceuticals, Inc. (PIRS). The company’s rating falls to D from the previous week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PIRS stock.

OpGen, Inc. (OPGN) slips from a C to a D this week. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of OPGN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.